Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Seres Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $46.64M, down 13.7% year over year. For fiscal 2025 it was $49.06M, down 24.1% from the year before. Over ten years it grew 2.6% a year on average. The highest annual figure on record is $141.89M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.06M | -24.1% |
| FY2024 | Dec 31, 2024 | $64.60M | -45.1% |
| FY2023 | Dec 31, 2023 | $117.60M | +7.2% |
| FY2022 | Dec 31, 2022 | $109.65M | -22.7% |
| FY2021 | Dec 31, 2021 | $141.89M | +56.7% |
| FY2020 | Dec 31, 2020 | $90.57M | +13.0% |
| FY2019 | Dec 31, 2019 | $80.14M | -16.5% |
| FY2018 | Dec 31, 2018 | $95.96M | +7.3% |
| FY2017 | Dec 31, 2017 | $89.46M | +9.1% |
| FY2016 | Dec 31, 2016 | $81.99M | +115.2% |
| FY2015 | Dec 31, 2015 | $38.10M | +255.4% |
| FY2014 | Dec 31, 2014 | $10.72M | +123.1% |
| FY2013 | Dec 31, 2013 | $4.81M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.14M | -29.4% |
| Q1 FY2026 | Mar 31, 2026 | $13.20M | +11.6% |
| Q4 FY2025 | Dec 31, 2025 | $11.68M | -9.0% |
| Q3 FY2025 | Sep 30, 2025 | $12.62M | -23.4% |
| Q2 FY2025 | Jun 30, 2025 | $12.94M | -18.1% |
| Q1 FY2025 | Mar 31, 2025 | $11.82M | -39.4% |
| Q4 FY2024 | Dec 31, 2024 | $12.84M | -44.3% |
| Q3 FY2024 | Sep 30, 2024 | $16.46M | -34.6% |
| Q2 FY2024 | Jun 30, 2024 | $15.81M | -66.2% |
| Q1 FY2024 | Mar 31, 2024 | $19.49M | -55.7% |
| Q4 FY2023 | Dec 31, 2023 | $23.04M | -50.1% |
| Q3 FY2023 | Sep 30, 2023 | $25.15M | -41.7% |
| Q2 FY2023 | Jun 30, 2023 | $46.79M | +6.5% |
| Q1 FY2023 | Mar 31, 2023 | $43.97M | +10.9% |
| Q4 FY2022 | Dec 31, 2022 | $46.22M | +25.8% |
| Q3 FY2022 | Sep 30, 2022 | $43.12M | +8.1% |
| Q2 FY2022 | Jun 30, 2022 | $43.94M | +22.2% |
| Q1 FY2022 | Mar 31, 2022 | $39.65M | +35.3% |
| Q4 FY2021 | Dec 31, 2021 | $36.75M | +47.8% |
| Q3 FY2021 | Sep 30, 2021 | $39.88M | +67.1% |
| Q2 FY2021 | Jun 30, 2021 | $35.95M | +78.9% |
| Q1 FY2021 | Mar 31, 2021 | $29.30M | +34.8% |
| Q4 FY2020 | Dec 31, 2020 | $24.87M | +18.2% |
| Q3 FY2020 | Sep 30, 2020 | $23.86M | +30.3% |
| Q2 FY2020 | Jun 30, 2020 | $20.10M | +12.3% |
| Q1 FY2020 | Mar 31, 2020 | $21.74M | -5.0% |
| Q4 FY2019 | Dec 31, 2019 | $21.03M | -15.1% |
| Q3 FY2019 | Sep 30, 2019 | $18.32M | -22.6% |
| Q2 FY2019 | Jun 30, 2019 | $17.91M | -25.6% |
| Q1 FY2019 | Mar 31, 2019 | $22.89M | -2.4% |
| Q4 FY2018 | Dec 31, 2018 | $24.77M | +3.0% |
| Q3 FY2018 | Sep 30, 2018 | $23.68M | +6.6% |
| Q2 FY2018 | Jun 30, 2018 | $24.05M | +4.3% |
| Q1 FY2018 | Mar 31, 2018 | $23.46M | +16.5% |
| Q4 FY2017 | Dec 31, 2017 | $24.04M | +18.7% |
| Q3 FY2017 | Sep 30, 2017 | $22.21M | -8.0% |
| Q2 FY2017 | Jun 30, 2017 | $23.06M | – |
| Q1 FY2017 | Mar 31, 2017 | $20.14M | – |
| Q4 FY2016 | Dec 31, 2016 | $20.26M | – |
| Q3 FY2016 | Sep 30, 2016 | $24.14M | – |
See a number that looks wrong?